Gris–Oliver and colleagues suggested that 64% of HER2-negative BC xenografts with resistance to eribulin (microtubule inhibitors) show PIK3CA, PIK3R1, or AKT1 mutation, indicating that PI3K pathway activation may induce resistance or early adaptation to microtubule inhibitors (45). This evidence concerns the gene PIK3CA and breast cancer.